Patents by Inventor Daniel Getts

Daniel Getts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BINDING DOMAINS AND METHODS OF USE THEREOF
    Publication number: 20250090663
    Abstract: Compositions and methods for binding to target antigens. Compositions comprising variable heavy chain domains with binding specificity to CD70, GPC3, IL13Ralpha2 and Cadherin CDH17 antigens.
    Type: Application
    Filed: September 13, 2024
    Publication date: March 20, 2025
    Inventors: Daniel Getts, Yuxiao Wang, Vania Emilova Ashminova, Thach Chu
  • Therapeutic cell compositions and methods of manufacturing and use thereof
    Patent number: 12252545
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: March 18, 2025
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Daniel Getts, Yuxiao Wang
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240391998
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Application
    Filed: May 24, 2024
    Publication date: November 28, 2024
    Inventors: Daniel Getts, Yuxiao Wang
  • MACROPHAGE SPECIFIC ENGAGER COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240327482
    Abstract: Compositions and methods for making and using therapeutic agents comprising myeloid cell specific engagers, used for immunotherapy of cancer or infection.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 3, 2024
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240252630
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Application
    Filed: February 6, 2024
    Publication date: August 1, 2024
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
  • Engineered chimeric fusion protein compositions and methods of use thereof
    Patent number: 12030938
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: July 9, 2024
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Daniel Getts, Yuxiao Wang
  • Engineered chimeric fusion protein compositions and methods of use thereof
    Patent number: 11944680
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Grant
    Filed: January 18, 2023
    Date of Patent: April 2, 2024
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
  • COVALENT POLYMER-ANTIGEN CONJUGATED PARTICLES
    Publication number: 20230338576
    Abstract: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).
    Type: Application
    Filed: October 24, 2022
    Publication date: October 26, 2023
    Inventors: Ryan Pearson, Daniel Getts, John Puisis, James Herrmann, Lonnie D. Shea
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230303684
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Application
    Filed: January 20, 2023
    Publication date: September 28, 2023
    Inventors: Daniel Getts, Yuxiao Wang
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230277659
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Application
    Filed: January 18, 2023
    Publication date: September 7, 2023
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, JR.
  • Methods and compositions for genomic integration
    Patent number: 11672874
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: June 13, 2023
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Daniel Getts, Yuxiao Wang, Namita Bisaria, Inna Shcherbakova, Socheata Ly
  • METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
    Publication number: 20230141052
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Application
    Filed: January 19, 2023
    Publication date: May 11, 2023
    Inventors: Daniel Getts, Yuxiao Wang, Namita Bisaria, Inna Shcherbakova, Socheata Ly
  • Engineered chimeric fusion protein compositions and methods of use thereof
    Patent number: 11628218
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: April 18, 2023
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
  • THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF
    Publication number: 20230046472
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Application
    Filed: June 10, 2022
    Publication date: February 16, 2023
    Inventors: Daniel Getts, Yuxiao Wang, Namita Bisaria, Kathryn Austgen, Caitlyn Anne Morrison Harvey, Patrick Mendes Tavares
  • METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
    Publication number: 20220411817
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Application
    Filed: June 30, 2022
    Publication date: December 29, 2022
    Inventors: Daniel Getts, Yuxiao Wang, Namita Bisaria, Inna Shcherbakova, Socheata Ly
  • Covalent polymer-antigen conjugated particles
    Patent number: 11510996
    Abstract: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: November 29, 2022
    Assignees: COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Ryan Pearson, Daniel Getts, John Puisis, James Herrmann, Lonnie D. Shea
  • METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
    Publication number: 20220364110
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 17, 2022
    Inventors: Daniel Getts, Yuxiao Wang, Namita Bisaria, Inna Shcherbakova, Socheata Ly
  • METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
    Publication number: 20220184230
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Application
    Filed: March 4, 2022
    Publication date: June 16, 2022
    Inventors: Daniel Getts, Yuxiao Wang, Namita Bisaria
  • THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF
    Publication number: 20210361703
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Application
    Filed: March 15, 2021
    Publication date: November 25, 2021
    Inventors: Daniel Getts, Yuxiao Wang
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING TARGET SPECIFIC FUSION PROTEINS
    Publication number: 20210315933
    Abstract: Provided herein are T cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more MUC16 or IL 13R?2 or MSLN TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: July 26, 2019
    Publication date: October 14, 2021
    Inventors: Patrick Alexander Baeuerle, Robert Hofmeister, Daniel Getts, Vania Ashminova, Jian Ding